News and Announcements
Oncosil Medical Investor Presentation August 2016
- Published August 22, 2016 10:17AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
22nd August 2016, ASX Announcement
Overview
- Developing an implantable radiotherapy medical device ‘OncosilTM’ for pancreatic and liver cancer
- CE Mark targeted in the near term followed by commercial launch and sales in UK, EU and Australia
- Technology platform suitable for multiple solid state tumours providing a more targeted therapy
- Global pancreatic cancer market > US1$B
- Global Pivotal Study underway – FDA approved IDE – July, 2016 Trial sites being engaged
- New leadership team – Daniel Kenny CEO (ex Baxter, Roche) and Dr Chris Roberts (ex Cochlear CEO) Chairman-elect
- Proprietary technology with robust patient portfolio
- ASX listed ~ $69m market cap and $13.4m of cash
Device Overview: Radiation therapy delivered directly into the tumour
- Pure “soft beta” radiation source (P32) to avoid systemic side effects
- Localised radiation therapy using “sticky” microparticles
- Carrier particles are inert silicon
- Particles are suspended in fluid to allow direct injection into the tumour
- Single Injection under anesthesia takes 30 minutes
- Local radiation in the tumour lasts around 3 months
To view the full Presentation, please click on the button below.